SCHEMBL24344307

SCHEMBL24344307

COc1ncnc(NC2CC2)c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.45
LMNA P02545 5/20 0.45
CYP1A2 P05177 5/20 0.45
CYP2C19 P33261 4/20 0.45
USP2 O75604 4/20 0.45
CLK4 Q9HAZ1 4/20 0.45
CYP2D6 P10635 3/20 0.45
TSHR P16473 3/20 0.45
MAPK1 P28482 2/20 0.45
ALDH1A1 P00352 1/20 0.45
ALOX15 P16050 1/20 0.45
IRAK4 Q9NWZ3 12/20 0.44
EGFR P00533 1/20 0.43
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
CHRM4 P08173 1/20 0.40
HSD17B10 Q99714 2/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24344303 0.81 IRAK4 (0.43) CYP3A4LMNACYP1A2CYP2C19USP2
SCHEMBL29534716 0.81 IRAK4 (0.43) CYP3A4LMNACYP1A2CYP2C19USP2
SCHEMBL12261899 0.76 YTHDC1 (0.39) CYP3A4LMNACYP1A2CYP2C19USP2
SCHEMBL20375579 0.74 CYP1A2 (0.44) CYP3A4LMNACYP1A2CYP2C19USP2
SCHEMBL30923912 0.72 BTK (0.42) IRAK4EGFR
SCHEMBL6796490 0.72 PDPK1 (0.45) LMNACYP1A2CYP2C19TSHRALDH1A1
SCHEMBL19004853 0.71 IRAK4 (0.43) CYP3A4LMNACYP1A2CYP2C19USP2
SCHEMBL27991639 0.70 EGFR (0.59) CYP3A4LMNACYP1A2CYP2D6EGFR
SCHEMBL22897343 0.70 EGFR (0.44) CYP3A4LMNACYP1A2CYP2D6EGFR
SCHEMBL25517459 0.69 PDPK1 (0.34) ALDH1A1CHRM4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076975-A1 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN THERAPEUTICS, INC. (US) 2022-04-14 WO disclosed